Ann: Completion of Placement, page-157

Do you Trust these faces? Have a closer look






TOP SHAREHOLDERS 12 MAY 2014

bioMérieux (licence partner for PREVI® Isola) 9.8%
L H Guthrie (LBT CEO) 5.5% SOLD SOME IN PEAK TIME
B Moran 4.8% ? NOT HOLDING ANYMORE
SA Pathology 4.7%
Avanteos Investments Ltd (1) 4.2%
R A Finder (LBT Chairman) 4.2%
Avanteos Investments Ltd (2) 2.9% F

Future Priorities Sign global distribution agreement for APAS® products (H2 2014)
Commence Australian and USA clinical trials for APAS® (H2 2014)
Achieve FDA US market approval for APAS® software (2015)
Achieve CE Mark for European markets for APAS®
(2015)
Commence Woundvue™ technology development project based on Intelligent Imaging platform (H2 2014)

Adelaide-based LBT Innovations founder Lusia Guthrie cashes in on rocketing share price

Valerina Changarathil, The Advertiser
October 18, 2016 5:07pm
Subscriber only

CO-FOUNDER and current adviser to Adelaide clinical and diagnostic technology developer LBT Innovations Lusia Guthrie has cashed in on the 337 per cent share price windfall generated by a recent US approval for one of the company’s products.

LBT Innovations’ share price has rocketed from a start of 19c on October 10 to a close of 83c yesterday.
The company yesterday revealed The Podlaska Super Fund, controlled by Lucyna (Lusia) Guthrie and Hugh Guthrie, had ceased to be a substantial holder in the company after selling down some of its stake in LBT Innovations.

The sale of 1.75 million shares over three trading days at an average price of between 64c and 96c, earned the Guthries $1.21 million.
The super fund still holds more than four million shares in LBT, but the shareholding now sits below 5 per cent, the threshold for substantial holding.
The company’s 2016 annual report shows the fund was the third largest shareholder at 5.40 per cent with more than 6 million shares as on September 19.

About a week ago the July 2006-listed Australian sharemarket entity announced it had received US Food and Drug Administration clearance for its culture plate analysis technology, Automated Plate Assessment Systems (APAS).

The imaging and software technology that automates a tedious manual process — the incubation, monitoring and analysis of the agar plates used to culture microorganisms — now has approval to be used as a Class II medical device in the US following successful clinical trials.

The automation process helps in faster diagnosis and reporting of infectious diseases and the clearance is likely to help fast-track its commercialisation and further development.
LBT Innovations and Swiss company Hettich AG’s joint venture, Clever Culture Systems, which is chaired by Ms Guthrie, is commercialising APAS.

http://www.adelaidenow.com.au/busin...e/news-story/2149fc534aaff04f4165b2d5d089ea83